Observation on the efficacy of Shuangdanmingmu capsules combined with larrupeptide in the treatment of diabetic

Objective: To study and explore the efficacy of Shuangdanmingmu capsule combined with larrupeptide in the treatment of diabetic retinopathy. Methods: 120 patients with diabetic retinopathy treated in our hospital from July 2020 to February 2022 were selected for study. They were randomly divided into control group, observation group 1 group and observation group 2 groups, each with 40 cases. The patients were treated routinely. The control group was treated with calcium hydroxybenzene sulfonate dispersible tablets, 1 group was observed to be treated with lirarupeptide + calcium hydroxybenzenesulfonate dispersible tablets, and 2 groups were given lirarupeptide treatment + Shuangdanmingmu capsules. The clinical efficacy, vision level, macular thickness, VEGF, IGF-1, incidence of adverse reactions and other indicators of the three groups were statistically compared. Results: The total efficiency of the observation group was 90.00%, the total efficiency of the observation group was 92.50%, and the total efficiency of the control group was 67.50% (P<0.05). There is no statistical difference in the overall efficiency of Observation Group 1 and Observation Group 2. After treatment, the vision level of the observation group 1 and the observation group 2 group was higher than that of the control group, and the macular thickness was lower than that of the control group (P<0.05). Conclusion: Shuangdanmingmu capsule combined with larrupeptide has a good effect in the treatment of diabetic retinopathy, can improve patients' vision, reduce macular edema, and have